Key result
Higher serum fetuin-A linked to insulin resistance and arterial stiffness in T2D, but not microangiopathies.
Why the study?
The relationship between serum fetuin-A levels, insulin resistance, metabolic syndrome, and vascular complications including cardiac autonomic neuropathy in T2DM patients was unclear.
Are serum fetuin-A levels associated with insulin resistance and vascular complications in patients with type 2 diabetes?
Cross-Sectional (n=172)
Are serum fetuin-A levels associated with insulin resistance and vascular complications in patients with type 2 diabetes?
Effect estimate: r = 0.196
p-value: p=0.022
Serum fetuin-A is associated with insulin resistance and arterial stiffness in patients with type 2 diabetes, but not with microvascular complications.
Fetuin-A associations with IR and CAN in T2DM remain hypothesis-generating; prospective studies needed before any clinical application.
OBJECTIVE: We examined the relationship between serum fetuin-A, insulin resistance (IR), metabolic syndrome (MS) and vascular complications including cardiac autonomic neuropathy (CAN) in patients with type 2 diabetes mellitus (T2DM). METHODS: A total of 172 T2DM patients were recruited and evaluated for diabetic microangiopathies (nephropathy, retinopathy and peripheral neuropathy) including CAN. Serum fetuin-A levels were measured by enzyme-linked immunosorbent assay (ELISA), and the IR was assessed by the index of homeostasis model [homeostasis model assessment-insulin resistance (HOMA-IR)]. Atherosclerotic burden was assessed by ankle-brachial index (ABI) and brachial-ankle pulse wave velocity (baPWV). RESULTS: Serum fetuin-A levels showed significant positive correlations with HOMA-IR (r = 0.196, p = 0.022), and the mean levels of HOMA-IR were significantly increased progressively across fetuin-A tertiles (p for trend = 0.044). Serum fetuin-A showed significant positive correlations with baPWV, systolic blood pressure (BP), total cholesterol, triglycerides, serum fasting c-peptide and negative correlations with ABI. Serum fetuin-A levels were also negatively correlated with serum adiponectin and positively correlated with serum tumour necrosis factor-α (TNF-α). The mean levels of serum fetuin-A were not significantly different according to the presence of each microangiopathies including CAN. Also, the mean levels of serum fetuin-A were not different between patients with MS and without MS. CONCLUSIONS: This present study showed that levels of serum fetuin-A are significantly associated with IR and arterial stiffness assessed by baPWV, while there are no associations with each microangiopathies in patients with T2DM.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2013) conducted a cross-sectional in Type 2 diabetes mellitus (n=172). Serum fetuin-A levels was evaluated on Correlation with HOMA-IR (r = 0.196, p=0.022). In patients with type 2 diabetes, serum fetuin-A levels were significantly associated with insulin resistance (r = 0.196, p = 0.022) and arterial stiffness, but not with microangiopathies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: